Celltex has submitted Emergency Expanded Access Clinical Study for Subjects with Coronavirus 2019 (COVID-19) using multiple dose Infusions of Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.
On March 21st, 2020, Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs) in the US. The team working on this expanded access protocol for COVID-19 consists of Dr. Jane Young, Chief Scientific Officer- Celltex and Dr. Derek W. Guillory, Principal Investigator-Root Causes Medicine San Antonio.
If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to firstname.lastname@example.org. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.
More Recent News
Houston company gets green light to study your own stem cells to prevent COVID-19
Promising news out of Houston from a company that got the FDA’s clearance to try to use a person’s own stem cells to prevent COVID-19. Celltex Therapeutics Corporation is also hoping the stem cells will help treat some of the more severe cases.Read More
Former U.S. Secretary of Energy and Texas Governor, Rick Perry, Names Two Texas Companies as Leading Innovators in the Fight Against COVID-19
Celltex Therapeutics obtains approval from FDA to evaluate Celltex’s Mesenchymal Stem Cells as prevention against COVID-19 and Medistar Corporation’s biodefense HVAC filter to destroy nearly 100% of the virusRead More